LONGSHENG FU¹, JINFANG HU¹, FENG SHAO², YAOQI WU¹, WEI BAI³, MINGJIN JIANG³, HAO CHEN⁴, LIHUA CHEN², YANNI LV^1,*

BIOCELL, Vol.47, No.8, pp. 1869-1883, 2023, DOI:10.32604/biocell.2023.028602

Abstract Background: Biochanin A is an excellent dietary isoflavone that has the concomitant function of both medicine and foodstuff. The attenuation function of biochanin A on blood-brain barrier (BBB) damage induced by cerebral ischemia-reperfusion remains unclear. Methods: C57BL/6 mice were subjected to 1 h middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. The infarct volume of the brain was stained by TTC, while leakage of the brain was quantitatively stained by Evans blue, and the neurologic deficit score was measured. Microglial-induced morphologic changes were observed via immunofluorescence staining, and rolling and adhering leukocytes in venules were observed via two-photon… More >

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*

Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942

Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients experience great side effects after… More > Graphic Abstract